Theravance Biopharma (NASDAQ: TBPH) recently received a number of ratings updates from brokerages and research firms:

  • 8/14/2019 – Theravance Biopharma was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 8/7/2019 – Theravance Biopharma was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 7/31/2019 – Theravance Biopharma was given a new $55.00 price target on by analysts at Piper Jaffray Companies. They now have a “buy” rating on the stock.
  • 7/30/2019 – Theravance Biopharma was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 7/2/2019 – Theravance Biopharma was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 6/19/2019 – Theravance Biopharma had its “positive” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $55.00 price target on the stock.

Shares of NASDAQ TBPH traded down $0.56 during mid-day trading on Wednesday, hitting $20.69. The company had a trading volume of 210 shares, compared to its average volume of 252,429. The stock has a market cap of $1.17 billion, a P/E ratio of -5.19 and a beta of 1.75. Theravance Biopharma Inc has a 1-year low of $15.18 and a 1-year high of $35.48. The business’s 50-day moving average price is $18.36.

Theravance Biopharma (NASDAQ:TBPH) last posted its quarterly earnings results on Wednesday, July 31st. The biopharmaceutical company reported ($0.72) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.22) by $0.50. Theravance Biopharma had a negative return on equity of 2,631.15% and a negative net margin of 369.67%. The company had revenue of $26.15 million for the quarter, compared to analysts’ expectations of $13.92 million. Equities research analysts predict that Theravance Biopharma Inc will post -4.28 earnings per share for the current year.

In other Theravance Biopharma news, Director Donal O’connor sold 4,000 shares of the firm’s stock in a transaction on Friday, May 17th. The stock was sold at an average price of $20.46, for a total value of $81,840.00. Following the sale, the director now directly owns 30,244 shares in the company, valued at $618,792.24. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 6.60% of the stock is owned by company insiders.

A number of institutional investors have recently bought and sold shares of TBPH. Norges Bank acquired a new stake in Theravance Biopharma in the fourth quarter valued at $22,422,000. BlackRock Inc. increased its position in shares of Theravance Biopharma by 3.1% during the second quarter. BlackRock Inc. now owns 3,832,682 shares of the biopharmaceutical company’s stock worth $62,587,000 after purchasing an additional 116,009 shares in the last quarter. Fosun International Ltd acquired a new stake in shares of Theravance Biopharma during the first quarter worth about $2,386,000. Bank of Montreal Can increased its position in shares of Theravance Biopharma by 28,276.0% during the second quarter. Bank of Montreal Can now owns 103,856 shares of the biopharmaceutical company’s stock worth $1,696,000 after purchasing an additional 103,490 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. increased its position in shares of Theravance Biopharma by 15.3% during the second quarter. Jacobs Levy Equity Management Inc. now owns 309,873 shares of the biopharmaceutical company’s stock worth $5,060,000 after purchasing an additional 41,060 shares in the last quarter. Institutional investors own 83.83% of the company’s stock.

Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines. The company offers VIBATIV, a bactericidal, once-daily injectable antibiotic to treat patients with serious, life-threatening infections due to staphylococcus aureus and other gram-positive bacteria, including methicillin-resistant.

Featured Article: Return on Investment (ROI)

Receive News & Ratings for Theravance Biopharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.